831 related articles for article (PubMed ID: 16231250)
21. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.
Craft JC; Moriarty SR; Clark K; Scott D; Degenhardt TP; Still JG; Corey GR; Das A; Fernandes P
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S520-6. PubMed ID: 21546629
[TBL] [Abstract][Full Text] [Related]
25. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
27. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
Giordano PA; Elston D; Akinlade BK; Weber K; Notario GF; Busman TA; Cifaldi M; Nilius AM
Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
[TBL] [Abstract][Full Text] [Related]
28. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
30. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.
Birmingham MC; Rayner CR; Meagher AK; Flavin SM; Batts DH; Schentag JJ
Clin Infect Dis; 2003 Jan; 36(2):159-68. PubMed ID: 12522747
[TBL] [Abstract][Full Text] [Related]
31. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
32. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
35. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
36. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.
Noel GJ; Draper MP; Hait H; Tanaka SK; Arbeit RD
Antimicrob Agents Chemother; 2012 Nov; 56(11):5650-4. PubMed ID: 22908151
[TBL] [Abstract][Full Text] [Related]
37. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
[TBL] [Abstract][Full Text] [Related]
38. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
39. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by Gram-positive pathogens.
Chen YS; Lee SC; Kim WJ
J Formos Med Assoc; 2004 May; 103(5):349-54. PubMed ID: 15216400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
